Skip to main content

1 Result(s)

within Amal Kataki Remove this filter Health Administration Remove this filter

and

  1. No Access

    Article

    Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women

    In this study, we evaluate the cost and outcomes of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus fulvestrant, fulvestrant alone, and conventional chemotherapy as the second-line therapy for hormone re...

    Nidhi Gupta, Dharna Gupta, Jyoti Dixit… in Applied Health Economics and Health Policy (2022)